Pharmacyte Biotech Inc., of Silver Spring, Md., raised an additional $1.02 million through a private placement with hopes to move into a pancreatic cancer clinical trial this year. Read More
Karyopharm Therapeutics Inc., of Newton, Mass., started Selinexor in Advanced Liposarcoma, or SEAL, a phase II/III trial with oral selinexor, the company's first-in-class, oral selective inhibitor of nuclear export compound that inhibits exportin 1. Read More
MMJ Phytotech Ltd., of Perth, Australia, reported that its wholly owned subsidiary, United Greeneries (UG), has received notification from Health Canada that a pre-license inspection of UG's Duncan, British Columbia-based facility will be conducted on Feb. 1. Read More
LONDON – An international commission examining the threat of infectious diseases in the light of the Ebola outbreak has recommended spending an additional $15 billion in a 15-year program of research to increase global preparedness against pandemics. Read More
In implementing the High Court's ruling that struck down Myriad Genetics Inc.'s claims to the BRCA1 gene, the Australia Patent Office is drawing several fine lines that could likely lead to additional court challenges. Read More
SAN FRANCISCO – The National Immunotherapy Coalition (NIC) received a big plug this week from President Barack Obama and from organizers of the 34th Annual J.P. Morgan Healthcare Conference (JPM), where a panel on the project was featured late Wednesday. Read More
SAN FRANCISCO – The J.P. Morgan Healthcare Conference might be reluctant to change, dedicated to the same (crowded) hotel venue for the past 34 years, but it is open to a rapidly growing group of attendees, inviting a substantial number of people from China. Read More
Detailed data from two phase IIb trials of the metabotropic glutamate receptor 5 (mGluR5) blocker mavoglurant (AFQ056, Novartis AG) for the treatment of Fragile X syndrome were published in Science Translational Medicine this week. Read More
While the marketing application in Europe remains under review, U.S. regulators' complete response letter (CRL) to Biomarin Pharmaceutical Inc. for Kyndrisa (drisapersen) in Duchenne muscular dystrophy (DMD) hardly stirred company backers, given the negative advisory committee (adcom) meeting in November. Read More
Valeant Pharmaceuticals International Inc., of Laval, Quebec, named Howard B. Schiller interim CEO, and Robert Ingram interim chairman of the board. Read More
